Crossing the next frontier
to give you a fair chance to fight
We develop novel therapeutic approaches against immune-mediated diseases,
that are more suited to chronic administration than current medicines,
especially in the majority of patients who have mild to moderate symptoms.
the next frontier...
Our lead program, EXL01, unleashes the therapeutic potential of a key player in the Microbiome - Host interactions to fight inflammatory bowel diseases, starting with Crohn's Disease. Our first clinical study is expected to start in 2022.
Our second program, EXL02, uses the ON/OFF switch of a recombinant protein to act directly on the modulation of the Tryptophan metabolism to fight several inflammatory diseases, starting with Rheumatoid Arthritis.
Our third program, EXL03, is a microbiome-based product targeting the AhR pathway to fight inflammatory skin diseases, starting with Atopic Dermatitis.
... to give you
a fair chance to fight
You, the patients, are the reason why leading researchers have joined forces in a pioneering translational approach called “Human Discovery First”.
We are committed to developing novel medicines with unprecedented benefit-risk ratio to allow greater access to treatment, especially for the majority of IMID patients who have mild to moderate symptoms.
Giving you a fair chance to fight is why we discovered unexplored therapeutic solutions, and why we founded Exeliom Biosciences.
Our research has led us to discover that patients suffering from inflammatory bowel diseases
lack a crucial bacterium and, therefore, do not have a fair chance to fight their conditions.
We have developed a single bacterial strain drug candidate to deliver first-in-class
microbiome-based therapeutics for the treatment of inflammatory bowel diseases (IBD),
starting with Crohn’s Disease as a first indication.
At Exeliom Biosciences, we are always thinking of the future without leaving the present behind.Discover
And this future, we intend to build it through partnerships.
Oops! Something went wrong while submitting the form.